Lyme disease therapeutic - LondonPharmaAlternative Names: Artemisinin-based Lyme disease therapeutic - LondonPharma; Lyme disease repurposed therapeutic - LondonPharma
Latest Information Update: 17 Dec 2014
Price : $50
At a glance
- Originator LondonPharma
- Class Artemisinins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Lyme disease
Most Recent Events
- 26 Nov 2014 Phase-I clinical trials in Lyme disease in United Kingdom (Sublingual) before November 2014
- 13 Jul 2014 Lyme disease therapeutic - LondonPharma is available for licensing as of 17 Dec 2014.